You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
乐普医疗(300003.SZ):2020年度净利预增0%-15%
格隆汇 01-30 16:15

格隆汇 1 月 30日丨乐普医疗(300003.SZ)披露2020年年度业绩预告,预计2020年年度归属于上市公司股东的净利润17.25亿元–19.84亿元,同比增长0%-15%;归属于上市公司股东的扣除非经常性损益的净利润13.65亿元–16.13亿元,同比增长10%-30%。业绩变动原因如下:

1、2020年前三季度公司经营正常,累计实现未经审计的扣除非经常性损益归属上市公司股东的净利润15.97亿元。

2、四季度,国家组织冠脉支架集中带量采购,由于经销商对集采的预期以及公司消化渠道的规划,支架产品实现很少销售。同时,渠道中存在的已售但未植入支架,公司有可能将通过退货或价格调整等方式予以处理,由此将形成大额损失计提。

四季度进一步加大研发投入,推进经导管主动脉瓣膜置换术(TAVR)、经导管二尖瓣修复系统、冷冻球囊、肾动脉消融导管、声波球囊、切割球囊、可降解封堵器系列产品、连续血糖监测系统、FFR导管、人工智能心电图机、监护仪等产品的研发进程,大幅增加研发支出。支架以外的其他业务,均延续正常运营趋势。

由于支架集采的影响和创新产品研发的大幅支出,尽管其他业务稳定增长,公司在第四季度有可能出现亏损。综合上述全年的业务情况,预计2020年公司实现扣除非经常性损益的归属于上市公司股东的净利润较去年同期的12.41亿元约有10%至30%的增长。

3、2020年,预计非经常性损益对公司归属于上市公司股东的净利润影响金额约为4亿元,与上年同期的4.85亿元相比有所下降。非经常性损益项目主要包括确认上海君实生物医药科技股份有限公司相关的未实现浮动收益及收到各类政府补助等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account